

Chloroquine (Pharmacogenomics)

Gene Testing May Be Considered

- [G6PD - Chloroquine](#)

Genes of Interest

- [Cytochrome P450 2D6](#)
- [Cytochrome P450 3A4](#)

Brand Names: Canada

TEVA-Chloroquine

Index Terms

Chloroquine Phosphate; Coronavirus; COVID-19

Pharmacologic Class

[Aminoquinoline \(Antimalarial\); Antimalarial Agent](#)

References

Advice for travelers. *The Medical Letter on Drugs and Therapeutics*. 2019 Oct;61(1582):153-160.

Akintonwa A, Gbajumo SA, and Mabadeje AF, "Placental and Milk Transfer of Chloroquine in Humans," *Ther Drug Monit*, 1988, 10(2):147-9.[\[PubMed 3381230\]](#)

American Society for Transplantation and Cellular Therapy (ASTCT). Interim guidelines for COVID-19 management in hematopoietic cell transplant and cellular therapy patients. [https://higherlogicdownload.s3.amazonaws.com/ASBMT/a1e2ac9a-36d2-4e23-945c-45118b667268/UploadedImages/COVID-19 Interim Patient Guidelines 3 18 20.pdf](https://higherlogicdownload.s3.amazonaws.com/ASBMT/a1e2ac9a-36d2-4e23-945c-45118b667268/UploadedImages/COVID-19%20Interim%20Patient%20Guidelines%203%2018%2020.pdf). Published March 18, 2020. Accessed March 24, 2020.

Anderson PO, Sauberan JB. Modeling drug passage into human milk. *Clin Pharmacol Ther*. 2016;100(1):42-52. doi: 10.1002/cpt.377.[\[PubMed 27060684\]](#)

Aralen (chloroquine phosphate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC: October 2018.

Aronoff GR, Bennett WM, Berns JS, et al, *Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children*. 5th ed. Philadelphia, PA: American College of Physicians; 2007:73.

ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. <https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6>.

Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, et al, "Incidence of Myopathy in Patients Treated With Antimalarials. A Report of Three Cases and a Review of the Literature," *Br J Rheumatol*, 1995, 34(2):166-70.[\[PubMed 7704464\]](#)

Bezerra EL, Vilar MJ, da Trindade Neto PB, et al. "Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus". *Arthritis Rheum*, 2005;52(10):3073-8. [\[PubMed 16200586\]](#)

Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. <http://www.idsociety.org/COVID19guidelines>. Updated April 21, 2020. Accessed April 22, 2020.

Boelaert JR, Yaro S, Augustijns P, Meda N, Schneider YJ, Schols D, Mols R, De Laere EA, Van de Perre P. Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. *AIDS*. 2001;15(16):2205-2207. [\[PubMed 11684948\]](#)

Bradley JS, Nelson JD, Barnett E, et al. *Nelson's Pediatric Antimicrobial Therapy*. 22nd ed. American Academy of Pediatrics; 2016.

Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. *Lancet*. 2008;371(9606):64-74. doi: 10.1016/S0140-6736(08)60073-2. Review. [\[PubMed 18177777\]](#)

Centers for Disease Control and Prevention (CDC), "CDC Health Information for International Travel 2018," New York: Oxford University Press, 2018.

Centers for Disease Control and Prevention. *CDC Yellow Book 2020: Travel-Related Infectious Diseases*. New York: Oxford University Press; 2019. Available at <https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria>.

Centers for Disease Control and Prevention (CDC), "Guidelines for Treatment of Malaria in the United States." Available at <http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf>

Centers for Disease Control and Prevention (CDC), "The Pre-Travel Consultation, Malaria." Available at <https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/malaria>

Centers for Disease Control and Prevention (CDC), "Treatment of Malaria (Guidelines for Clinicians)." Available at <http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf>

Centers for Disease Control and Prevention, "Malaria Prescription Drug Information for Healthcare Providers." Available at http://www.cdc.gov/malaria/travel/drugs_hcp.htm.

Chukwuani MC, Bolaji OO, Onyeji CO, Makinde ON, Ogunbona FA. Evidence for increased metabolism of chloroquine during the early third trimester of human pregnancy. *Trop Med Int Health*. 2004;9(5):601-605. [\[PubMed 15117305\]](#)

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 [published online March 10, 2020]. *J Crit Care*. doi: 10.1016/j.jcrr.2020.03.005. [\[PubMed 32173110\]](#)

Deturmeny E, Viala A, Durand A, Nosny Y. Chloroquine transfer to milk. A case. *Therapie*. 1984;39(4):438-440. [\[PubMed 6484889\]](#)

Edstein MD, Veenendaal JR, Newman K, Hyslop R. Excretion of chloroquine, dapsone and primethamine in human milk. *Br J Clin Pharmacol*. 1986;22(6):733-735. [\[PubMed 3567020\]](#)

Essien EE and Afamefuna GC, "Chloroquine and Its Metabolites in Human Cord Blood, Neonatal Blood, and Urine After Maternal Medication," *Clin Chem*, 1982, 28(5):1148-52. [\[PubMed 7074895\]](#)

Ette EI, Essien EE, Ogonor JI, Brown-Awala EA. Chloroquine in human milk. *J Clin Pharmacol*. 1987;27(7):499-502. [\[PubMed 3655001\]](#)

Fakeye TO, Fehintola FA, Ademowo OG, Walker O. Therapeutic monitoring of chloroquine in pregnant women with malaria. *West Afr J Med*. 2002;21(4):286-287. [\[PubMed 12665265\]](#)

FDA Safety Alert. MedWatch. Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. Food and Drug Administration website.

<https://www.fda.gov/media/136535/download>. Accessed April 1, 2020.

Ferreira AO, Polonini HC, Silva SL, Patrício FB, Brandão MAF, Raposo NRB. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend(®) SF PH4 oral suspensions. *J Pharm Biomed Anal*. 2016;118:105-112. [\[PubMed 26540625\]](#)

Freedman, DO, "Clinical Practice. Malaria Prevention in Short-Term Travelers," *N Engl J Med*, 2008, 359(6):603-612. [\[PubMed 18687641\]](#)

Gaffar R, Pineau CA, Bernatsky S, Scott S, Vinet É. Risk of ocular anomalies in children exposed in utero to antimalarials: a systematic literature review. *Arthritis Care Res (Hoboken)*. 2019;71(12):1606-1610. doi:10.1002/acr.23808 [\[PubMed 30418703\]](#)

Gallo CB, Luiz AC, Ferrazzo KL, Migliari DA, Sugaya NN. Drug-induced pigmentation of hard palate and skin due to chronic chloroquine therapy: report of two cases. *Clin Exp Dermatol*. 2009;34(7):e266–e267. [\[PubMed 19438573\]](#)

Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Foundation for Medical Education and Research. Preprint. Posted online March 25, 2020. *Mayo Clin Proc*.

https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_covid19.pdf

Glader B. Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed November 20, 2017. [\[PubMed 18687641\]](#)

Hill DR, Ericsson CD, Pearson RD, et al, "The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America," *Clin Infect Dis*, 2006, 43(12):1499-539. [\[PubMed 17109284\]](#)

Horta-Baas G. Chloroquine-induced oral mucosal hyperpigmentation and nail dyschromia. *Reumatol Clin*. 2018;14(3):177–178. [\[PubMed 17109284\]](#)

Ito S. Drug therapy for breast-feeding women. *N Engl J Med*. 2000;343(2):118-26. [\[PubMed 10891521\]](#)

Karunajeewa HA, Salman S, Mueller I, Baiwog F, et al. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. *Antimicrob Agents Chemother*. 2010;54(3):1186-1192. doi: 10.1128/AAC.01269-09.[\[PubMed 20086162\]](#)

Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. *Clin Pharmacokinet*. 1996;30(4):263-299. doi:10.2165/00003088-199630040-00002[\[PubMed 8983859\]](#)

Law I, Ilett KF, Hackett LP, et al, "Transfer of Chloroquine and Desethylchloroquine Across the Placenta and Into Milk in Melanesian Mothers," *Br J Clin Pharmacol*, 2008, 65(5):674-9.[\[PubMed 18279478\]](#)

Lee SJ, McGready R, Fernandez C, et al. Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. *Eur J Clin Pharmacol*. 2008;64(10):987-992. doi: 10.1007/s00228-008-0500-z.[\[PubMed 18594802\]](#)

Lesiak A, Narbutt J, Kobos J, et al. "Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis". *Clin Exp Dermatol*. 2009, 34(5):570-5. doi: 10.1111/j.1365-2230.2008.03006.x. Epub 2008 Dec 10.[\[PubMed 19077101\]](#)

Liu AC, "Hepatotoxic Reaction to Chloroquine Phosphate in a Patient With Previously Unrecognized Porphyria Cutanea Tarda," *West J Med*, 1995, 162(6):548-51.[\[PubMed 7618323\]](#)

Luzzatto L, Nannelli C, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. *Hematol Oncol Clin North Am*. 2016;30(2):373-93. doi:10.1016/j.hoc.2015.11.006. Review.[\[PubMed 27040960\]](#)

Mandi G, Witte S, Meissner P, et al. Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. *Trop Med Int Health*. 2005;10(1):32-38.[\[PubMed 15655011\]](#)

Manger K, von Streitberg U, Seitz G, Kleyer A, Manger B. Hard palate hyperpigmentation-a rare side effect of antimalarials. *Arthritis Rheumatol*. 2018;70(1):152.[\[PubMed 15655011\]](#)

Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). *Ophthalmology*. 2016;123(6):1386-1394. doi: 10.1016/j.ophtha.2016.01.058.[\[PubMed 26992838\]](#)

Massele AY, Kilewo C, Aden Abdi Y, et al. Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy. *Eur J Clin Pharmacol*. 1997;52(4):299-305.[\[PubMed 9248769\]](#)

McCreary EK, Pogue JM. COVID-19 treatment: a review of early and emerging options. Published March 23, 2020. Available at <https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofaa105/5811022>.

Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy [published correction appears in *JAMA Ophthalmol*. 2014;132(12):1493]. *JAMA Ophthalmol*. 2014;132(12):1453-1460.[\[PubMed 25275721\]](#)

Mirochnick M, Barnett E, Clarke DF, et al, "Stability of Chloroquine in an Extemporaneously Prepared Suspension Stored at Three Temperatures," *Pediatr Infect Dis J*, 1994, 13(9):827-8.[\[PubMed 7808855\]](#)

Ogunbona FA, Onyeji CO, Bolaji OO, Torimiro SE. Excretion of chloroquine and desethylchloroquine in human milk. *Br J Clin Pharmacol*. 1987;23(4):473-476.[\[PubMed 3580253\]](#)

Olafuyi O, Badhan RKS. Dose optimization of chloroquine by pharmacokinetic modeling during pregnancy for the treatment of Zika virus infection. *J Pharm Sci*. 2019;108(1):661-673. doi:10.1016/j.xphs.2018.10.056[\[PubMed 30399360\]](#)

Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. *J Rheumatol*. 2011;38(12):2504-2508. doi:10.3899/jrheum.110686[\[PubMed 22002012\]](#)

Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in *Circulation*. 2016;134(12):e261]. *Circulation*. 2016;134(6):e32-e69.[\[PubMed 27400984\]](#)

Salako LA, Walker O, Iyuan AO. Pharmacokinetics of chloroquine in renal insufficiency. *Afr J Med Med Sci*. 1984;13(3-4):177-182.[\[PubMed 6099980\]](#)

Salman S, Baiwog F, Page-Sharp M, et al. Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. *Int J Antimicrob Agents*. 2017;50(4):542-551. doi: 10.1016/j.ijantimicag.2017.05.011.[\[PubMed 28669839\]](#)

Seidel J, "Diagnosis and Management of Amebic Liver Abscess in Children," *West J Med*, 1984, 140(6):932-3.[\[PubMed 6146229\]](#)

Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26. Epub 2015 Nov 6. Review.[\[PubMed 26545940\]](#)

Tony JC, Martin TK. Profile of amebic liver abscess. *Arch Med Res*. 1992;23(2):249-250.[\[PubMed 1340305\]](#)

US Department of Health and Human Services (HHS) Panel on COVID-19 Treatment Guidelines. Coronavirus disease 2019 (COVID-19) treatment guidelines. <https://covid19treatmentguidelines.nih.gov>. Updated April 21, 2020. Accessed April 22, 2020.

US Food and Drug Administration (FDA). Fact sheet for health care providers: emergency use authorization (EUA) for chloroquine phosphate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. <https://www.fda.gov/media/136535/download>. Published March 28, 2020. Accessed March 31, 2020.[\[PubMed 26540625\]](#)

van den Borne BE, Landewe RB, Rietveld JH, et al, "Chloroquine Therapy in Patients With Recent-Onset Rheumatoid Arthritis: The Clinical Response Can Be Predicted by the Low Level of Acute-Phase Reaction at Baseline," *Clin Rheumatol*, 1999, 18(5):369-72.[\[PubMed 10524550\]](#)

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020;30(3):269-271. doi: 10.1038/s41422-020-0282-0. [[PubMed 32020029](#)]

White NJ, "Cardiotoxicity of Antimalarial Drugs," *Lancet Infect Dis*, 2007, 7(8):549-58. [[PubMed 17646028](#)]

Wilby KJ and Ensom MH, "Pharmacokinetics of Antimalarials in Pregnancy: A Systematic Review," *Clin Pharmacokinet*, 2011, 50(11):705-23. [[PubMed 21973268](#)]

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/

World Health Organization (WHO). Guidelines for the Treatment of Malaria. 3rd edition. Geneva: World Health Organization; 2015. Available at <https://www.who.int/malaria/publications/atoz/9789241549127/en/>

Yap YG and Camm AJ, "Drug Induced QT Prolongation and Torsades de Pointes," *Heart*, 2003, 89(11):1363-72. [[PubMed 14594906](#)]

Youngster I, Arcavi L, Schechmaster R, Akayzen Y, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. *Drug Saf*. 2010;33(9):713-726. doi:10.2165/11536520-000000000-00000. Review. [[PubMed 20701405](#)]

Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression [published online March 20, 2020]. *J Antimicrob Chemother*. 2020. doi:10.1093/jac/dkaa114 [[PubMed 32196083](#)]

Last Updated 4/24/20